Stoke Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Stoke Therapeutics, Inc. carries a market capitalization of 1.80B, placing it among publicly traded companies globally.
| Market Cap | 1.80B |
| Enterprise Value | N/A |
Share Statistics
Stoke Therapeutics, Inc. currently has 62.24M shares outstanding.
| Shares Outstanding | 62.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Stoke Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 45.99. The price-to-sales ratio is 60.91, and the price-to-book ratio stands at -3.57.
| PE Ratio | 45.99 |
| PS Ratio | 60.91 |
| PB Ratio | -3.57 |
| P/TBV Ratio | 4.95 |
| P/FCF Ratio | -13.39 |
| P/OCF Ratio | -13.31 |
Financial Position
Stoke Therapeutics, Inc. maintains a current ratio of 8.99, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.99 |
| Quick Ratio | 8.57 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.28M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Stoke Therapeutics, Inc.'s stock has gained approximately 164.67431% over the past 52 weeks. The 50-day moving average sits at 32.88, while the 200-day moving average is 30.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | 164.67431% |
| 50-Day Moving Average | 32.88 |
| 200-Day Moving Average | 30.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Stoke Therapeutics, Inc. generated 32.08M in revenue and converted that into -169.77M in net income, yielding earnings per share of -2.83. EBITDA reached -183.52M, while operating income came in at -185.25M.
| Revenue | 32.08M |
| Gross Profit | N/A |
| Operating Income | -185.25M |
| Pretax Income | -171.04M |
| Net Income | -169.77M |
| EBITDA | -183.52M |
| EBIT | -185.25M |
| Earnings Per Share (EPS) | -2.83 |
Balance Sheet
Total book value stands at -547.71M, with working capital of 325.88M providing operational flexibility.
| Cash & Cash Equivalents | 343.55M |
| Total Debt | N/A |
| Net Debt | -155.66M |
| Equity (Book Value) | -547.71M |
| Book Value Per Share | -9.13 |
| Working Capital | 325.88M |
Cash Flow
Stoke Therapeutics, Inc. produced -146.82M in operating cash flow over the past twelve months. After subtracting -871,000.00 in capital expenditures, free cash flow totaled -147.69M - equivalent to -2.46 per share.
| Operating Cash Flow | -146.82M |
| Capital Expenditures | -871,000.00 |
| Free Cash Flow | -147.69M |
| FCF Per Share | -2.46 |
Margins
Stoke Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -577.46 and net profit margin of -529.20 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -577.46 |
| Pretax Margin | -533.18 |
| Profit Margin | -529.20 |
| EBITDA Margin | -572.06 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.23 |
| FCF Yield | -7.47 |
Scores
Stoke Therapeutics, Inc. posts an Altman Z-Score of 22.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.07 |